Comparative Prospective Study Of Effectiveness And Safety Of Atorvastatin And Rosuvastatin In Patients With Dyslipidemia At A Tertiary Care Teaching Hospital Of Bihar

Dr. Preety Priya; Dr.Sanjay Kumar; Dr. (prof) Sanjay Kumar

Volume : VIII, Issue : VII, July - 2019

Comparative Prospective Study Of Effectiveness And Safety Of Atorvastatin And Rosuvastatin In Patients With Dyslipidemia At A Tertiary Care Teaching Hospital Of Bihar

Dr. Preety Priya, Dr. Sanjay Kumar, Dr. Prof Sanjay Kumar

Abstract :

Background: Hyperlipidemia is a major cause of atherosclerosis and atherosclerosis-associated conditions, such as coronary heart disease (CHD), ischemic cereovascular disease and peripheral vascular disease. The aim and objective of this study was to compare effectiveness and safety of the hypolipidemic drugs Atorvastatin (10mg) and Rosuvastatin (5mg) in patients with Dyslipidemia. Materials & Methods:The study was conducted at Nalanda Medical College & Hospital,Patna during the period from october 2018 to march 2019. It was a open,randomized, prospective, comparative & observational study. 100 patients of age group 30 -69 yrs were selected on basis of inclusion and exclusion criteria from Medicine OPD. They were randomly divided into two groups of 50 each. Atorvastatin 10mg once daily was given to Group A and Rosuvastatin 5 mg once daily was given to Group B. The level of TC, TG, LDL, VLDL and HDL were assessed at Start of therapy (baseline) and at the end of 3 months and 6 months. Result: LDL was reduced significantly more with 5mg Rosuvastatin than with Atorvastatin 10 mg [43.68% vs. 40.74% (P 0.0049)] after 3 month of therapy. Rosuvastatin 5mg reduced LDL significantly more than Atorvastatin 10 mg [48.69% vs. 43.85% (P 0.00)]. TC, HDL, TG and VLDL were more favourably modified by Rosuvastatin at 6 months (P <0.005). Reduction of total cholesterol levels in Rosuvastatin group was not statistically significant when compared with Atorvastatin group. Conclusion: Rosuvastatin 5mg was more effective than Atorvastatin 10mg for the improvement of lipid profile after 6 months of drug therapy in patients with dyslipidemia